PIPELINE

  • Oncology

    • OGB23501

      Target (P.O.C) Candidate Lead Non-clinical Phase Clinical PhaseⅠ Clinical PhaseⅡ Clinical PhaseⅢ
      OGB23501

      OGB23501

      OGB23501 is a long-acting triple immuno-oncologic agent based on UniStac for non-small cell lung cancer, melanoma, renal cancer, and liver cancer. This molecule was designed to maximize its therapeutic effects for both immune-infiltrating and immune-excluded tumors by inhibiting Immune checkpoint protein and vascular growth factor in tumor environment. We aimed to overcome the acquired resistance and increase the success rate for the development by targeting the clinically validated antigens at the same time.

    • OGB23502

      Target (P.O.C) Candidate Lead Non-clinical Phase Clinical PhaseⅠ Clinical PhaseⅡ Clinical PhaseⅢ
      OGB23502

      OGB23502

      OGB23502 is a UniStac-based triple immuno-oncologic agent for treating B-cell neoplasms. It was designed to increase its anti-cancer effects by targeting cancer-cell specific receptors and activating immune cells at the same time. Especially, now that dual antibody and CAR-T were successfully developed and are being used for the treatment of B cell-associated blood cancers, OGB23502 is expected to show excellent anticancer effects through amplified immune responses by controlling three different antigens at once.

  • OGB23503

    Target (P.O.C) Candidate Lead Non-clinical Phase Clinical PhaseⅠ Clinical PhaseⅡ Clinical PhaseⅢ
    OGB23503

    OGB23502

    OGB23502는 B 세포 혈액암 치료를 위한 UniStac 기반의 3중 면역항암제이다. 암 세포 특이적 수용체를 표적하고 동시에 면역세포를 활성화시켜 항암효과를 증대시키고자 고안하였다. 특히 B 세포 연관 혈액암의 경우 이중항체 및 CAR-T 등의 치료제가 성공적으로 개발되어 치료에 사용되어지고 있기 때문에 3개의 항원을 동시에 조절하여 면역반응 증폭을 통한 우수한 항암 효과를 보일 것으로 기대하고 있다.